Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
about
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsA place for precision medicine in bladder cancer: targeting the FGFRs.Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Expression of FGFR3 Protein and Gene Amplification in Urinary Bladder Lesions in Relation to Schistosomiasis.Targeted sequencing of tonsillar and base of tongue cancer and human papillomavirus positive unknown primary of the head and neck reveals prognostic effects of mutated FGFR3.Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLCGATA3 in the urinary bladder: suppression of neoplastic transformation and down-regulation by androgensModelling bladder cancer in mice: opportunities and challenges.Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder CancersTrichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivoFGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More AttentionOptimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.Targeted therapies in bladder cancer: an overview of in vivo research.Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.Recent progress with next-generation biomarkers in muscle-invasive bladder cancer.Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing.Achondroplasia: Development, pathogenesis, and therapy.Sleeping beauty: awakening urothelium from its slumber.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.
P2860
Q26801718-64304CF5-35D0-4B16-958A-65BCDAADE364Q30249143-68E036D9-5375-4B07-B0AC-52A7C5CC396BQ30857433-9AB16A1E-D44C-4B0F-895E-E78E7C9EC04BQ33625843-AA11F21E-56A8-4BCC-83BF-E479DD6F3AF5Q33646072-3D17DBF5-2248-424D-A3DD-FC5591A7C0ECQ33798848-1931AD64-C413-4EED-A236-7FC9CF9F502AQ34135320-17D32592-F0AF-4508-A23D-6C1332813192Q34178465-B121C22C-C893-41D8-AE13-3F33D0A6662AQ35285703-DECB17AC-B7A0-44A4-9C40-63970AEFB493Q36146337-D6B56A62-2EC9-4948-B5A8-E75C01F2CEBBQ36192868-F3F342A2-FC6B-4D82-9204-08AF6139F14BQ37295668-CF5C68DE-17B1-42E0-835B-A3C1FA9AEBC0Q37462489-A91B66B3-DBED-45BE-81EB-1E75FC5DEA68Q37510049-D65C4D60-978E-4248-897F-B1FB945ABF63Q37527255-4D26A423-C407-4E47-A60E-0CA15B6517F6Q38195217-48DE1A36-1148-416C-9C3B-E07AA60E15ABQ38590471-0FA0A896-3833-416C-A306-68938FF95C7CQ38852690-8822CA0D-942D-4DA5-B3E8-691A70F148F0Q38946859-89BBA469-258A-4C1A-9766-BC7BE148051AQ39036906-5762D7F3-5014-4DEA-A5C3-471E70B8178DQ39041957-59963C3A-79B9-40CB-A644-354CD3616ADAQ39103374-D7F25BF0-496F-478E-8E33-B4707D677D74Q39560208-5D939EAF-A409-4411-986C-85CE471D8AF5Q43115752-5AFD626D-CF4B-4874-83A6-79BB4AF21EBCQ49456418-4CC3244A-9560-4EE8-A650-36372D80407DQ49728493-C240382A-7789-432C-8AA3-E936811C1AA7
P2860
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
@en
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
@nl
type
label
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
@en
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
@nl
prefLabel
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
@en
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer.
@nl
P2093
P2860
P1476
Fibroblast growth factor receptor 3 is a rational therapeutic target in bladder cancer
@en
P2093
Avi Ashkenazi
Bogdan Czerniak
Colin P Dinney
David J McConkey
Jolanta Bondaruk
Kilian M Gust
Paul K Hegarty
Peter C Black
Shannon Awrey
P2860
P304
P356
10.1158/1535-7163.MCT-12-1150
P577
2013-05-08T00:00:00Z